Oncotarget

Research Papers:

Prognostic role of neutrophil lymphocyte ratio in patients with glioma

Jing Zhang, Sunfu Zhang, Yanlin Song, Min He, Qingqing Ren, Chaoyue Chen, Zhiyong Liu, Yunhui Zeng and Jianguo Xu _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:59217-59224. https://doi.org/10.18632/oncotarget.19484

Metrics: PDF 3372 views  |   HTML 1926 views  |   ?  


Abstract

Jing Zhang1,*, Sunfu Zhang1,*, Yanlin Song2,*, Min He1, Qingqing Ren1, Chaoyue Chen1, Zhiyong Liu1, Yunhui Zeng1 and Jianguo Xu1

1Department of Neurosurgery, West China Hospital of Sichuan University, The First People’s Hospital of Yibin, Sichuan, PR China

2West China School of Medicine, West China Hospital of Sichuan University, Sichuan, PR China

*These authors have contributed equally to this work

Correspondence to:

Jianguo Xu, email: jianguo_1229@126.com

Keywords: neutrophil lymphocyte ratio, glioma, survival, prognosis

Received: April 27, 2017    Accepted: June 20, 2017    Published: July 22, 2017

ABSTRACT

The purpose of this study was to evaluate the prognostic role of neutrophil lymphocyte ratio (NLR) in patients with glioma. PubMed, EMBASE, Cochrane Library and China National Knowledge Infrastructure were searched for relevant literature. The study and patient characteristics were extracted. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled to estimate the prognostic role of NLR in patients with glioma. Subgroup analysis and sensitivity analysis were also performed. Six studies with 1,021 patients were included. The pooled HR of elevated NLR for OS in patients with glioma was 1.48 (95% CI, 1.25-1.76). Among the included studies, five studies used 4 as the cut-off value of NLR. The pooled HR for OS of the five studies was 1.67 (95% CI, 1.37-2.03). No significant heterogeneity was observed (I2 = 42.4%, P=0. 122). Publication bias was not present. Elevated NLR was associated with poorer overall survival in patients with glioma.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 19484